Immunotherapy

1. Gene symbol

 

↓ Add multiple genes

Multi-gene analysis

Multi-gene method: Mean expression

Configure multi-gene analysis

Add gene list here:

Separate genes with spaces, commas, or line breaks. Check the "Multi-gene analysis" box to integrate genes into a signature.

Validate and Add Genes

2. Response

Combined response (n=1,434)

3. Treatment

Anti PD-1 (CD279) therapy

any anti PD-1

nivolumab

pembrolizumab

Anti PD-L1 (CD274) therapy

any anti PD-L1

atezolizumab

durvalumab

Anti CTLA4 (CD152) therapy

any anti CTLA-4

ipilimumab

Any

any immune checkpoint inhibitor therapy

Total: 0

Non-responders: 0

Responders: 0

Counts reflect available expression data for the selected gene(s) after applying the filters. When multiple genes are selected, the displayed values correspond to the gene with the lowest eligible sample count.A multi-gene analysis may include fewer samples because complete expression data are required for all selected genes in the same patients.

4. Filters (optional)

Sample acquisition All Pretreatment (n = 1267) Ontreatment (n = 167)

Gender All Male (n = 801) Female (n = 350)

Primary tumor All No (n = 164) Yes (n = 552)

Metastatic All No (n = 120) Yes (n = 988)

5. Settings

Tissue of origin Bladder Breast Colorectal Esophageal Adeno Gastric Cancer Glioblastoma Head And Neck Squamous Cell Carcinoma Hepatocellular Carcinoma Melanoma Non Small Cell Lung Cancer Non Squamous Lung Cancer Renal Cell Carcinoma Small Cell Lung Cancer Squamous Lung Cancer Ureter/ Renal Pelvis Urothelial All

No outliers

Show quartiles

JetSet only

Show ROC grid

Show threshold points

Show 95% confidence band

Color: non-responder

Color: responder

ROC curve color

Calculate

By using the services, you agree to be bound by the Terms of Use.

Please kindly cite our paper to support further development: Kovacs SA, Fekete JT, Gyorffy B.: Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors, Acta Pharmacol Sin., 2023 Apr 13.; doi: 10.1038/s41401-023-01079-6.